NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $114.68 -1.39 (-1.20 %) (As of 05/19/2019 04:00 PM ET)Previous Close$114.68Today's Range$112.06 - $116.0452-Week Range$98.56 - $278.62Volume255,477 shsAverage Volume343,429 shsMarket Capitalization$2.25 billionP/E Ratio18.26Dividend YieldN/ABeta1.33 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. Receive LGND News and Ratings via Email Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND Previous Symbol CUSIP53220K50 CIK886163 Webwww.ligand.com Phone858-550-7500Debt Debt-to-Equity Ratio0.57 Current Ratio8.39 Quick Ratio8.33Price-To-Earnings Trailing P/E Ratio18.26 Forward P/E Ratio49.01 P/E Growth2.45 Sales & Book Value Annual Sales$251.45 million Price / Sales8.97 Cash Flow$9.3769 per share Price / Cash Flow12.23 Book Value$54.92 per share Price / Book2.09Profitability EPS (Most Recent Fiscal Year)$6.28 Net Income$143.32 million Net Margins320.12% Return on Equity19.21% Return on Assets7.96%Miscellaneous Employees116 Outstanding Shares19,660,000Market Cap$2.25 billion Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported $1.16 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.28. The biotechnology company had revenue of $43.48 million for the quarter, compared to analyst estimates of $38.28 million. Ligand Pharmaceuticals had a net margin of 320.12% and a return on equity of 19.21%. Ligand Pharmaceuticals's quarterly revenue was down 22.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.55 EPS. View Ligand Pharmaceuticals' Earnings History. When is Ligand Pharmaceuticals' next earnings date? Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Ligand Pharmaceuticals. What price target have analysts set for LGND? 6 brokers have issued 12 month target prices for Ligand Pharmaceuticals' shares. Their forecasts range from $150.00 to $260.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $218.00 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals. What is the consensus analysts' recommendation for Ligand Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals. What are Wall Street analysts saying about Ligand Pharmaceuticals stock? Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019) 2. According to Zacks Investment Research, "Ligand reported encouraging fourth-quarter results, beating estimates on both counts. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. Shares of Ligand have underperformed the industry so far this year. Following the sale Promacta rights, the company will derive a substantial portion of its revenues from royalties associated with the sales of Kyprolis. The drug has shown encouraging growth and will achieve blockbuster status in 2019. However, any setback related to this product could have a substantial impact." (3/27/2019) Has Ligand Pharmaceuticals been receiving favorable news coverage? News stories about LGND stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are some of Ligand Pharmaceuticals' key competitors? Some companies that are related to Ligand Pharmaceuticals include Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH) and Ascendis Pharma A/S (ASND). What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Illumina (ILMN), Netflix (NFLX), Alibaba Group (BABA), Gilead Sciences (GILD), salesforce.com (CRM), Palo Alto Networks (PANW) and Adobe (ADBE). Who are Ligand Pharmaceuticals' key executives? Ligand Pharmaceuticals' management team includes the folowing people: Mr. John L. Higgins, CEO & Exec. Director (Age 49)Mr. Matthew W. Foehr, Pres & COO (Age 46)Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Todd Pettingill, Director of Corp. Devel. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.93%), Renaissance Technologies LLC (7.20%), Janus Henderson Group PLC (7.04%), William Blair Investment Management LLC (4.51%), Victory Capital Management Inc. (3.33%) and Conestoga Capital Advisors LLC (3.04%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals. Which major investors are selling Ligand Pharmaceuticals stock? LGND stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Eagle Asset Management Inc., Morgan Stanley, Marshall Wace LLP, William Blair Investment Management LLC, Oak Ridge Investments LLC, Renaissance Technologies LLC and FMR LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals. Which major investors are buying Ligand Pharmaceuticals stock? LGND stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Wellington Management Group LLP, The Manufacturers Life Insurance Company , Conestoga Capital Advisors LLC, Elk Creek Partners LLC, State of New Jersey Common Pension Fund D and Rice Hall James & Associates LLC. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh and John L Higgins. View Insider Buying and Selling for Ligand Pharmaceuticals. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $114.68. How big of a company is Ligand Pharmaceuticals? Ligand Pharmaceuticals has a market capitalization of $2.25 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe. What is Ligand Pharmaceuticals' official website? The official website for Ligand Pharmaceuticals is http://www.ligand.com. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected] MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 442 (Vote Outperform)Underperform Votes: 292 (Vote Underperform)Total Votes: 734MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What Are Treasury Bonds? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.